The 8th Cardiovascular Outcome Trial (CVOT) Summit on Cardiovascular, Kidney, and Glycemic Outcomes was held virtually on November 10-12, 2022. Following the tradition of previous summits, this reference congress served as a platform for in-depth discussion and exchange on recently completed outcomes trials as well as key trials important to the cardiovascular (CV) field. This year's focus was on the results of the DELIVER, EMPA-KIDNEY and SURMOUNT-1 trials and their implications for the treatment of heart failure (HF) and chronic kidney disease (CKD) with sodium-glucose cotransporter-2 (SGLT2) inhibitors and obesity with glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists. A broad audience of primary care physicians, diabetologists, endocrinologists, cardiologists, and nephrologists participated online in discussions on new consensus recommendations and guideline updates on type 2 diabetes (T2D) and CKD management, overcoming clinical inertia, glycemic markers, continuous glucose monitoring (CGM), novel insulin preparations, combination therapy, and reclassification of T2D. The impact of cardiovascular outcomes on the design of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) trials, as well as the impact of real-world evidence (RWE) studies on the confirmation of CVOT outcomes and clinical trial design, were also intensively discussed. The 9th Cardiovascular Outcome Trial Summit will be held virtually on November 23-24, 2023 ( http://www.cvot.org ).

3rd Medical Department and Laboratory for Endocrinology and Metabolism 1st Faculty of Medicine Charles University Prague Czech Republic

Altman Clinical and Translational Research Institute La Jolla CA USA

Cardiovascular division Brigham and Women's Hospital Boston MA USA

Center for Diabetes Research Gentofte Hospital University of Copenhagen Hellerup Denmark

Center Internal Medicine Fünf Höfe Munich Germany

Clalit Health Services and Technion Faculty of Medicine Haifa Israel

Credit Valley Hospital Mississauga ON Canada

CRS Clinical Research Services Mannheim GmbH Mannheim Germany

Department of Clinical Medicine University of Copenhagen Copenhagen Denmark

Department of Clinical Pharmacy and Pharmacology University Medical Center Groningen University of Groningen Groningen The Netherlands

Department of Diabetes Central Medical School Monash University Melbourne Australia

Department of Endocrinology Catholic University Leuven Leuven Belgium

Department of Family Medicine Acıbadem Mehmet Ali Aydınlar University School of Medicine Istanbul Turkey

Department of Internal Medicine 4 University Clinic Tübingen Tübingen Germany

Department of Medicine K2 Karolinska Institute Stockholm Sweden

Department of Nephrology University of Helsinki and Helsinki University Hospital Helsinki Finland

Department of Precision and Regenerative Medicine and Ionian Area University of Bari Aldo Moro Bari Italy

Diabetes Division St Josef Hospital Ruhr University Bochum Bochum Germany

Diabetes Research Centre University of Leicester Leicester UK

Division of Endocrinology Department of Medicine and Duke Clinical Research Institute Duke University School of Medicine Durham NC USA

Division of Nephrology and Hypertension Medical Center University of Kansas Kansas City KS USA

Eli Lilly and Company Indianapolis IN USA

Endocrine and Metabolic Consultants Rockville MD USA

Faculty of Medicine University of Ljubljana Ljubljana Slovenia

Folkhälsan Institute of Genetics Folkhälsan Research Center Biomedicum Helsinki University of Helsinki Helsinki Finland

Forschergruppe Diabetes e 5 Helmholtz Center Munich Ingolstaedter Landstraße 1 Neuherberg 85764 Germany

German Center for Diabetes Research Tübingen Germany

Institute for Diabetes Research and Metabolic Diseases at the Eberhard Karls University of Tübingen Tübingen Germany

Institute of Life Course and Medical Sciences University of Liverpool Liverpool UK

International Diabetes Center at Park Nicollet Health Partners Minneapolis MN USA

IRCCS MultiMedica Milan Italy

Manchester University Foundation Trust Manchester UK

NIHR Biomedical Research Centre Leicester UK

Peking University People's Hospital Xicheng District Beijing China

Pontifical Catholic University of Paraná Curitiba Brazil

ProSciento Inc San Diego CA USA

Sciarc GmbH Baierbrunn Germany

Shupyk National Medical Academy of Postgraduate Education Kiev Ukraine

Steno Diabetes Center Copenhagen Herlev Denmark

Taking Control of Your Diabetes Solana Beach CA USA

Thorax Institute University Hospital of Nantes Nantes France

University Children's Hospital Ljubljana Slovenia

University Medical Center Ljubljana Slovenia

Zobrazit více v PubMed

International Diabetes Federation: IDF Diabetes Atlas, 10th edn. Brussels, Belgium. 2021. https://www.diabetesatlas.org. Accessed 22 February 2022.

Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2021 doi: 10.1016/j.diabres.2021.109119. PubMed DOI PMC

Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol. 2018;17(1):83. doi: 10.1186/s12933-018-0728-6. PubMed DOI PMC

Emerging Risk Factors C, Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215–22. doi: 10.1016/S0140-6736(10)60484-9. PubMed DOI PMC

Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol CJASN. 2017;12(12):2032–2045. doi: 10.2215/CJN.11491116. PubMed DOI PMC

American Diabetes Association Standards of medical care in diabetes—2021. Diabetes Care. 2021;44(1):S1–S232. PubMed

Wen CP, Chang CH, Tsai MK, Lee JH, Lu PJ, Tsai SP, et al. Diabetes with early kidney involvement may shorten life expectancy by 16 years. Kidney Int. 2017;92(2):388–396. doi: 10.1016/j.kint.2017.01.030. PubMed DOI

Regier EE, Venkat MV, Close KL. More than 7 years of hindsight: revisiting the FDA's 2008 guidance on cardiovascular outcomes trials for type 2 diabetes medications. Clin Diabetes. 2016;34(4):173–180. doi: 10.2337/cd16-0005. PubMed DOI PMC

U.S. Food and Drug Administration. Guidance for industry diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. 2008. https://www.fda.gov/media/71297/download. Accessed 22 February 2022.

Hernandez AF, Green JB, Janmohamed S, D'Agostino RB, Sr, Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519–1529. doi: 10.1016/S0140-6736(18)32261-X. PubMed DOI

Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228–1239. doi: 10.1056/NEJMoa1612917. PubMed DOI PMC

Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322. doi: 10.1056/NEJMoa1603827. PubMed DOI PMC

Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Kober LV, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247–2257. doi: 10.1056/NEJMoa1509225. PubMed DOI

Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–1844. doi: 10.1056/NEJMoa1607141. PubMed DOI

Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med. 2021;385(10):896–907. doi: 10.1056/NEJMoa2108269. PubMed DOI

Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–1326. doi: 10.1056/NEJMoa1307684. PubMed DOI

Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232–242. doi: 10.1056/NEJMoa1501352. PubMed DOI

White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–1335. doi: 10.1056/NEJMoa1305889. PubMed DOI

Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the carmelina randomized clinical trial. JAMA. 2019;321(1):69–79. doi: 10.1001/jama.2018.18269. PubMed DOI PMC

Rosenstock J, Kahn SE, Johansen OE, Zinman B, Espeland MA, Woerle HJ, et al. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the carolina randomized clinical trial. JAMA. 2019;322(12):1155–1166. doi: 10.1001/jama.2019.13772. PubMed DOI PMC

Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657. doi: 10.1056/NEJMoa1611925. PubMed DOI

Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–357. doi: 10.1056/NEJMoa1812389. PubMed DOI

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128. doi: 10.1056/NEJMoa1504720. PubMed DOI

Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383(15):1425–1435. doi: 10.1056/NEJMoa2004967. PubMed DOI

Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2020;384:129–139. doi: 10.1056/NEJMoa2030186. PubMed DOI

Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451–1461. doi: 10.1056/NEJMoa2107038. PubMed DOI

Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385(24):2252–2263. doi: 10.1056/NEJMoa2110956. PubMed DOI

Solomon SD, McMurray JJV, Claggett B, De Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089–98. PubMed

Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2022 doi: 10.1056/NEJMoa2204233. PubMed DOI PMC

Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–216. doi: 10.1056/NEJMoa2206038. PubMed DOI

Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121–130. doi: 10.1016/S0140-6736(19)31149-3. PubMed DOI

Lam CSP, Ramasundarahettige C, Branch KRH, Sattar N, Rosenstock J, Pratley R, et al. Efpeglenatide and clinical outcomes with and without concomitant sodium-glucose cotransporter-2 inhibition use in type 2 diabetes: exploratory analysis of the AMPLITUDE-O trial. Circulation. 2022;145(8):565–574. doi: 10.1161/CIRCULATIONAHA.121.057934. PubMed DOI

Pop-Busui R, Januzzi JL, Bruemmer D, Butalia S, Green JB, Horton WB, et al. Heart failure: an underappreciated complication of diabetes a consensus report of the American diabetes association. Diabetes Care. 2022;45(7):1670–90. doi: 10.2337/dci22-0014. PubMed DOI PMC

Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force for diabetes, pre-diabetes, and cardiovascular diseases of the European society of Cardiology (ESC) and the European association for the study of diabetes (EASD) Eur Heart J. 2019;41(2):255–323. doi: 10.1093/eurheartj/ehz486. PubMed DOI

Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of hyperglycaemia in type 2 diabetes, 2022 a consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD) Diabetologia. 2022 doi: 10.1007/s00125-022-05787-2. PubMed DOI PMC

Schnell O, Standl E, Cos X, Heerspink HJL, Itzhak B, Lalic N, et al. Report from the 5th cardiovascular outcome trial (CVOT) summit. Cardiovasc Diabetol. 2020;19(1):47. doi: 10.1186/s12933-020-01022-7. PubMed DOI PMC

Schnell O, Standl E, Catrinoiu D, Itzhak B, Lalic N, Rahelic D, et al. Report from the 4th cardiovascular outcome trial (CVOT) summit of the diabetes & cardiovascular disease (D&CVD) EASD study group. Cardiovasc Diabetol. 2019;18(1):30. doi: 10.1186/s12933-019-0822-4. PubMed DOI PMC

Schnell O, Standl E, Catrinoiu D, Genovese S, Lalic N, Lalic K, et al. Report from the 3rd cardiovascular outcome trial (CVOT) summit of the diabetes & cardiovascular disease (D&CVD) EASD study group. Cardiovasc Diabetol. 2018;17(1):30. doi: 10.1186/s12933-018-0667-2. PubMed DOI PMC

Schnell O, Standl E, Catrinoiu D, Genovese S, Lalic N, Skra J, et al. Report from the 2nd cardiovascular outcome trial (CVOT) summit of the diabetes and cardiovascular disease (D&CVD) EASD study group. Cardiovasc Diabetol. 2017;16(1):35. doi: 10.1186/s12933-017-0508-8. PubMed DOI PMC

Schnell O, Standl E, Catrinoiu D, Genovese S, Lalic N, Skra J, et al. Report from the 1st cardiovascular outcome trial (CVOT) summit of the diabetes & cardiovascular disease (D&CVD) EASD study group. Cardiovasc Diabetol. 2016;15:33. doi: 10.1186/s12933-016-0357-x. PubMed DOI PMC

Schnell O, Cos X, Cosentino F, Forst T, Giorgino F, Heersprink HJL, et al. Report from the CVOT summit 2020: new cardiovascular and renal outcomes. Cardiovasc Diabetol. 2021;20(1):75. doi: 10.1186/s12933-021-01254-1. PubMed DOI PMC

Frias JP, Choi J, Rosenstock J, Popescu L, Niemoeller E, Muehlen-Bartmer I, et al. Efficacy and safety of once-weekly efpeglenatide monotherapy versus placebo in type 2 diabetes: the AMPLITUDE-M randomized controlled trial. Diabetes Care. 2022;45(7):1592–1600. doi: 10.2337/dc21-2656. PubMed DOI PMC

El Mikati IK, Khabsa J, Harb T, Khamis M, Agarwal A, Pardo-Hernandez H, et al. A framework for the development of living practice guidelines in health care. Ann Intern Med. 2022;175(8):1154–1160. doi: 10.7326/M22-0514. PubMed DOI

Schnell O, Battelino T, Bergenstal R, Blüher M, Böhm M, Brosius F, et al. Report from the CVOT summit 2021: new cardiovascular, renal, and glycemic outcomes. Cardiovasc Diabetol. 2022;21(1):50. doi: 10.1186/s12933-022-01481-0. PubMed DOI PMC

Marx N, Ryden L, Brosius F, Ceriello A, Cheung M, Cosentino F, et al. Proceedings of the guideline workshop 2019—Strategies for the optimization of guideline processes in diabetes, cardiovascular diseases and kidney diseases. Diabetes Res Clin Pract. 2020;162:108092. doi: 10.1016/j.diabres.2020.108092. PubMed DOI

Li S, Vandvik PO, Lytvyn L, Guyatt GH, Palmer SC, Rodriguez-Gutierrez R, et al. SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline. BMJ. 2021;373:n1091. doi: 10.1136/bmj.n1091. PubMed DOI

Palmer SC, Tendal B, Mustafa RA, Vandvik PO, Li S, Hao Q, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2021;372:m4573. doi: 10.1136/bmj.m4573. PubMed DOI PMC

Nelson AJ, O’Brien EC, Kaltenbach LA, Green JB, Lopes RD, Morse CG, et al. Use of lipid-, blood pressure–, and glucose-lowering pharmacotherapy in patients with type 2 diabetes and atherosclerotic cardiovascular disease. JAMA Netw Open. 2022;5(2):e2148030. doi: 10.1001/jamanetworkopen.2021.48030. PubMed DOI PMC

Nelson AJ, Pagidipati NJ, Kelsey MD, Ardissino M, Aroda VR, Cavender MA, et al. Coordinating cardiology clinics randomized trial of interventions to improve outcomes (COORDINATE)—Diabetes: rationale and design. Am Heart J. 2023;256:2–12. doi: 10.1016/j.ahj.2022.10.079. PubMed DOI

Ahlqvist E, Storm P, Käräjämäki A, Martinell M, Dorkhan M, Carlsson A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 2018;6(5):361–369. doi: 10.1016/S2213-8587(18)30051-2. PubMed DOI

Zaharia OP, Strassburger K, Strom A, Bönhof GJ, Karusheva Y, Antoniou S, et al. Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study. Lancet Diabetes Endocrinol. 2019;7(9):684–694. doi: 10.1016/S2213-8587(19)30187-1. PubMed DOI

Pigeyre M, Hess S, Gomez MF, Asplund O, Groop L, Paré G, et al. Validation of the classification for type 2 diabetes into five subgroups: a report from the ORIGIN trial. Diabetologia. 2022;65(1):206–215. doi: 10.1007/s00125-021-05567-4. PubMed DOI

Schrader S, Perfilyev A, Ahlqvist E, Groop L, Vaag A, Martinell M, et al. Novel subgroups of type 2 diabetes display different epigenetic patterns that associate with future diabetic complications. Diabetes Care. 2022;45(7):1621–1630. doi: 10.2337/dc21-2489. PubMed DOI PMC

Wagner R, Heni M, Tabák AG, Machann J, Schick F, Randrianarisoa E, et al. Pathophysiology-based subphenotyping of individuals at elevated risk for type 2 diabetes. Nat Med. 2021;27(1):49–57. doi: 10.1038/s41591-020-1116-9. PubMed DOI

Fang M, Wang D, Coresh J, Selvin E. Trends in diabetes treatment and control in US adults, 1999–2018. N Engl J Med. 2021;384(23):2219–28. doi: 10.1056/NEJMsa2032271. PubMed DOI PMC

Laiteerapong N, Ham SA, Gao Y, Moffet HH, Liu JY, Huang ES, et al. The legacy effect in type 2 diabetes: impact of early glycemic control on future complications (the diabetes & aging study) Diabetes Care. 2019;42(3):416–426. doi: 10.2337/dc17-1144. PubMed DOI PMC

Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019;42(8):1593–1603. doi: 10.2337/dci19-0028. PubMed DOI PMC

Martens T, Beck RW, Bailey R, Ruedy KJ, Calhoun P, Peters AL, et al. Effect of continuous glucose monitoring on glycemic control in patients with type 2 diabetes treated with basal insulin: a randomized clinical trial. JAMA. 2021;325(22):2262–2272. doi: 10.1001/jama.2021.7444. PubMed DOI PMC

Davis G, Bailey R, Calhoun P, Price D, Beck RW. Magnitude of glycemic improvement in patients with type 2 diabetes treated with basal insulin: subgroup analyses from the MOBILE study. Diabetes Technol Ther. 2022;24(5):324–331. doi: 10.1089/dia.2021.0489. PubMed DOI PMC

Committee ADAPP. 7 Diabetes technology: standards of medical care in diabetes—2022. Diabetes Care. 2021;45(1):S97–S112. PubMed

Bergenstal RM. Understanding continuous glucose monitoring data. 2018 Aug. In: Role of Continuous Glucose Monitoring in Diabetes Treatment. Arlington (VA): American Diabetes Association; 2018. 10.2337/db20181-20. PubMed

Isaacs D, Cox C, Schwab K, Oser TK, Rinker J, Mason MJ, et al. Technology integration: the role of the diabetes care and education specialist in practice. Diabetes Educ. 2020;46(4):323–334. doi: 10.1177/0145721720935123. PubMed DOI

Bergenstal RM, Simonson GD, Heinemann L. More green, less red: how color standardization may facilitate effective use of CGM data. J Diabetes Sci Technol. 2022;16(1):3–6. doi: 10.1177/19322968211053341. PubMed DOI PMC

Nauck M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab. 2016;18(3):203–216. doi: 10.1111/dom.12591. PubMed DOI PMC

Polonsky WH, Giorgino F, Rosenstock J, Whitmire K, Lew E, Coudert M, et al. Improved patient-reported outcomes with iGlarLixi versus premix BIAsp 30 in people with type 2 diabetes in the SoliMix trial. Diabetes Obes Metab. 2022;24(12):2364–2372. doi: 10.1111/dom.14822. PubMed DOI PMC

Levin P, Hoogwerf BJ, Snell-Bergeon J, Vigers T, Pyle L, Bromberger L. Ultra rapid-acting inhaled insulin improves glucose control in patients with type 2 diabetes mellitus. Endocr Pract. 2021;27(5):449–454. doi: 10.1016/j.eprac.2020.10.004. PubMed DOI

Khan AB, Ahmad A, Ahmad S, Gul M, Iqbal F, Ullah H, et al. Comparative analysis of inhaled insulin with other types in type 1 diabetes mellitus: a systematic review and meta-analysis. Cureus. 2022;14(4):e23731. PubMed PMC

Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71(4):793–801. doi: 10.1016/j.jhep.2019.06.021. PubMed DOI

Kasper P, Martin A, Lang S, Kütting F, Goeser T, Demir M, et al. NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol. 2021;110(7):921–937. doi: 10.1007/s00392-020-01709-7. PubMed DOI PMC

KDIGO Clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;102(5s):S1–s127. PubMed

von Scholten BJ, Kreiner FF, Rasmussen S, Rossing P, Idorn T. The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practice. Ther Adv Endocrinol Metab. 2022;13:20420188221112490. PubMed PMC

de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, et al. Diabetes management in chronic kidney disease: a consensus report by the American diabetes association (ADA) and kidney disease: improving global outcomes (KDIGO) Diabetes Care. 2022;45(12):3075–3090. doi: 10.2337/dci22-0027. PubMed DOI PMC

Rossing P, Baeres FMM, Bakris G, Bosch-Traberg H, Gislum M, Gough SCL, et al. The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrol Dial Transpl. 2023 doi: 10.1093/ndt/gfad009. PubMed DOI PMC

Lingvay I, Sumithran P, Cohen RV, le Roux CW. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. Lancet. 2022;399(10322):394–405. doi: 10.1016/S0140-6736(21)01919-X. PubMed DOI

Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503–515. doi: 10.1056/NEJMoa2107519. PubMed DOI

US Food and Drug Administration. Framework for FDA’s real world evidence program. Updated December 2018. Available at: https://www.fda.gov/downloads/ScienceResearch/SpecialTopics/RealWorldEvidence/UCM627769.pdf. Accessed 6 February 2023.

Cave A, Kurz X, Arlett P. Real-world data for regulatory decision making: challenges and possible solutions for Europe. Clin Pharmacol Ther. 2019;106(1):36–39. doi: 10.1002/cpt.1426. PubMed DOI PMC

Concato J, Corrigan-Curay J. Real-world evidence—where are we now? N Engl J Med. 2022;386(18):1680–1682. doi: 10.1056/NEJMp2200089. PubMed DOI

Saturni S, Bellini F, Braido F, Paggiaro P, Sanduzzi A, Scichilone N, et al. Randomized controlled trials and real life studies approaches and methodologies: a clinical point of view. Pulm Pharmacol Ther. 2014;27(2):129–38. doi: 10.1016/j.pupt.2014.01.005. PubMed DOI

Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors) Circulation. 2017;136(3):249–259. doi: 10.1161/CIRCULATIONAHA.117.029190. PubMed DOI PMC

Cavender MA, Norhammar A, Birkeland KI, Jørgensen ME, Wilding JP, Khunti K, et al. SGLT-2 inhibitors and cardiovascular risk: an analysis of CVD-REAL. J Am Coll Cardiol. 2018;71(22):2497–2506. doi: 10.1016/j.jacc.2018.01.085. PubMed DOI

Evans M, Husain M, Frenkel O, Kant Magla K, Srivastava A, Lingvay I. Risk of stroke in patients with type 2 diabetes receiving semaglutide or a dipeptidyl peptidase-4 inhibitor: a real-world US claims database analysis. Eur Heart J. 2022 doi: 10.1093/eurheartj/ehac544.1939. PubMed DOI

Pecoits-Filho R, James G, Carrero JJ, Wittbrodt E, Fishbane S, Sultan AA, et al. Methods and rationale of the DISCOVER CKD global observational study. Clin Kidney J. 2021;14(6):1570–1578. doi: 10.1093/ckj/sfab046. PubMed DOI PMC

CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes